Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study.


Journal

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
ISSN: 1827-1936
Titre abrégé: Q J Nucl Med Mol Imaging
Pays: Italy
ID NLM: 101213861

Informations de publication

Date de publication:
Dec 2022
Historique:
pubmed: 17 6 2020
medline: 18 11 2022
entrez: 17 6 2020
Statut: ppublish

Résumé

Radiomic features are increasingly utilized to evaluate tumor heterogeneity in PET imaging but to date its role has not been investigated for Cho-PET in prostate cancer. The potential application of radiomics features analysis using a machine-learning radiomics algorithm was evaluated to select We retrospectively analyzed high-risk PCa patients who underwent restaging One hundred and six imaging features were extracted for 46 lesions for a total of 4876 features analyzed. No significant differences between the training and validating sets in terms of age, sex, PSA values, lesion location and size (P>0.05) were demonstrated by the machine-learning model. Thirteen features were able to discriminate FU disease status after NCA selection. Best performance in DA classification was obtained using the combination of the 13 selected features (sensitivity 74%, specificity 58% and accuracy 66%) compared to the use of all features (sensitivity 40%, specificity 52%, and accuracy 51%). Per-site performance of the 13 selected features in DA classification were as follows: T = sensitivity 63%, specificity 83%, accuracy 71%; N = sensitivity 87%, specificity 91% of and accuracy 90%; bone-M = sensitivity 33%, specificity 77% and accuracy 66%. An artificial intelligence model demonstrated to be feasible and able to select a panel of

Sections du résumé

BACKGROUND BACKGROUND
Radiomic features are increasingly utilized to evaluate tumor heterogeneity in PET imaging but to date its role has not been investigated for Cho-PET in prostate cancer. The potential application of radiomics features analysis using a machine-learning radiomics algorithm was evaluated to select
METHODS METHODS
We retrospectively analyzed high-risk PCa patients who underwent restaging
RESULTS RESULTS
One hundred and six imaging features were extracted for 46 lesions for a total of 4876 features analyzed. No significant differences between the training and validating sets in terms of age, sex, PSA values, lesion location and size (P>0.05) were demonstrated by the machine-learning model. Thirteen features were able to discriminate FU disease status after NCA selection. Best performance in DA classification was obtained using the combination of the 13 selected features (sensitivity 74%, specificity 58% and accuracy 66%) compared to the use of all features (sensitivity 40%, specificity 52%, and accuracy 51%). Per-site performance of the 13 selected features in DA classification were as follows: T = sensitivity 63%, specificity 83%, accuracy 71%; N = sensitivity 87%, specificity 91% of and accuracy 90%; bone-M = sensitivity 33%, specificity 77% and accuracy 66%.
CONCLUSIONS CONCLUSIONS
An artificial intelligence model demonstrated to be feasible and able to select a panel of

Identifiants

pubmed: 32543166
pii: S1824-4785.20.03227-6
doi: 10.23736/S1824-4785.20.03227-6
doi:

Substances chimiques

Choline N91BDP6H0X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

352-360

Auteurs

Pierpaolo Alongi (P)

Unit of Nuclear Medicine, Fondazione Istituto G. Giglio, Cefalù, Palermo, Italy - alongi.pierpaolo@gmail.com.

Riccardo Laudicella (R)

Unit of Nuclear Medicine, Fondazione Istituto G. Giglio, Cefalù, Palermo, Italy.
Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, University of Messina, Messina, Italy.

Alessandro Stefano (A)

Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Cefalù, Palermo, Italy.

Federico Caobelli (F)

Clinic of Radiology and Nuclear Medicine, Basel University Hospital, University of Basel, Basel, Switzerland.

Albert Comelli (A)

Ri.MED Foundation, Palermo, Italy.
Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Cefalù, Palermo, Italy.
Department of Industrial and Digital Innovation (DIID), University of Palermo, Palermo, Italy.

Antonio Vento (A)

Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, University of Messina, Messina, Italy.

Davide Sardina (D)

Laboratory of Cellular and Molecular Pathophysiology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy.

Gloria Ganduscio (G)

Laboratory of Cellular and Molecular Pathophysiology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy.

Patrizia Toia (P)

Section of Radiology, Department of Biopathology and Medical Biotechnologies (DIBIMED), University of Palermo, Palermo, Italy.

Francesco Ceci (F)

Unit of Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, Italy.

Paola Mapelli (P)

Vita-Salute San Raffaele University, Milan, Italy.
Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Maria Picchio (M)

Vita-Salute San Raffaele University, Milan, Italy.
Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Massimo Midiri (M)

Section of Radiology, Department of Biopathology and Medical Biotechnologies (DIBIMED), University of Palermo, Palermo, Italy.

Sergio Baldari (S)

Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, University of Messina, Messina, Italy.

Roberto Lagalla (R)

Section of Radiology, Department of Biopathology and Medical Biotechnologies (DIBIMED), University of Palermo, Palermo, Italy.

Giorgio Russo (G)

Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Cefalù, Palermo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH